11.01.12
Teva
3Q Revenues: $5.0 billion (+14%)
3Q Loss: $79.0 million (earnings were $916 million 3Q11)
YTD Revenues: $15.1 billion (+20%)
YTD Earnings: $1.6 billion (-27%)
Comments: Generic revenues in the quarter were $2.5 billion (including API sales of $195 million), up 1%. Branded revenues in the quarter were $2.0 billion, up 38%, primarily due to the inclusion of Cephalon's medicines (mainly Treanda with $160 million, Nuvigil with $94 million and Provigil with $53 million). Also, Copaxone sales increased 13% to $1.1 billion. OTC revenues were $252 million, up 38%. Earnings in the quarter were impacted by a provision for a loss contingency of $670 million relating to patent litigation, and in-process R&D of $481 million.
3Q Revenues: $5.0 billion (+14%)
3Q Loss: $79.0 million (earnings were $916 million 3Q11)
YTD Revenues: $15.1 billion (+20%)
YTD Earnings: $1.6 billion (-27%)
Comments: Generic revenues in the quarter were $2.5 billion (including API sales of $195 million), up 1%. Branded revenues in the quarter were $2.0 billion, up 38%, primarily due to the inclusion of Cephalon's medicines (mainly Treanda with $160 million, Nuvigil with $94 million and Provigil with $53 million). Also, Copaxone sales increased 13% to $1.1 billion. OTC revenues were $252 million, up 38%. Earnings in the quarter were impacted by a provision for a loss contingency of $670 million relating to patent litigation, and in-process R&D of $481 million.